A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

Human immunodeficiency virus type 2 (HIV-2) has already spread to different regions worldwide, and currently about 1 to 2 million people have been infected, calling for new antiviral agents that are effective on both HIV-1 and HIV-2 isolates. T20 (enfuvirtide), a 36-mer peptide derived from the C-te...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Virol
Glavni autori: Xiong, Shengwen, Borrego, Pedro, Ding, Xiaohui, Zhu, Yuanmei, Martins, Andreia, Chong, Huihui, Taveira, Nuno, He, Yuxian
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2016
Teme:
Vaccines and Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5165200/
https://ncbi.nlm.nih.gov/pubmed/27795437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.01839-16
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items